SBIR-STTR Award

Rapid chemiluminescent assay for lutenizing hormone
Award last edited on: 3/1/02

Sponsored Program
SBIR
Awarding Agency
NIH : NICHD
Total Award Amount
$358,450
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
John C Voyta

Company Information

Tropix Inc (AKA: Quest Systems Inc)

47 Wiggins Avenue
Bedford, MA 01730
   (781) 271-0045
   info@tropix.com
   www.tropix.com
Location: Single
Congr. District: 06
County: Middlesex

Phase I

Contract Number: 1R43HD026205-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1989
Phase I Amount
$50,000
This project will generate a rapid chemiluminescence-based immunoassay for urinary luteinizing hormone (LH). A prototype system based on a membrane-supported, two-site sandwich immunoassay with an alkaline phosphatase-labeled detector antibody will be developed. Incorporation of 3-(2'adamantane)-4-(3'phosphoryloxy)phenyl-1,2dioxetane (AMPPD) will be investigated. Dephosphorylation of AMPPD with alkaline phosphatase results in a glow of light that will be detected with Polaroid instant film. Peak LH levels will be detected as a white spot on the film, in contrast to black or gray spots imaged when LH concentration is low. The film-based results will provide the user with a permanent record, which will facilitate day-to-day comparisons for both patients and their physicians. Phase II of this program will involve the design and engineering of a disposable unidose device and a prototype of a disposable imaging instrument. This LH assay kit will then be tested with clinically relevant LH-containing specimens.

Anticipated Results:
This rapid, easy-to-interpret LH assay will be marketed for at-home determination of fertility.National Institute Of Child Health And Human Development

Phase II

Contract Number: 2R44HD026205-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1991
(last award dollars: 1992)
Phase II Amount
$308,450

In this application, a proposal to generate a rapid chemiluminescence based immunoassay for urinary luteinizing hormone is described. A prototype system based on a membrane supported, two-site sandwich immunoassay, with an alkaline phosphatase labeled detector antibody will be developed. Incorporation of 3- (2'adamantane)-4-(3" phosphoryloxy)phenyl-1,2-dioxetane, (AMPPD), will be investigated. Dephosphorylation of AMPPD with alkaline phosphatase results in a glow of light which will be detected with Polaroid instant film. Peak LH levels will be detected as a white spot on the film, in contrast to black or gray spots imaged when LH concentration is low. The film-based results will provide the user a permanent record which will facilitate day to day comparisons, for both patients and their physician. Phase II of this program will involve the design and engineering of a disposable unidose device and a prototype of a disposable imaging instrument. This LH assay kit will then be tested with clinically relevant LH containing specimen